These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1611 related items for PubMed ID: 16782410

  • 1. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM, Schiffrin EL.
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [Abstract] [Full Text] [Related]

  • 2. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
    Marx N, Duez H, Fruchart JC, Staels B.
    Circ Res; 2004 May 14; 94(9):1168-78. PubMed ID: 15142970
    [Abstract] [Full Text] [Related]

  • 3. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
    Chinetti-Gbaguidi G, Fruchart JC, Staels B.
    Biomarkers; 2005 Nov 14; 10 Suppl 1():S30-6. PubMed ID: 16298909
    [Abstract] [Full Text] [Related]

  • 4. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
    Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fiévet C.
    Arterioscler Thromb Vasc Biol; 2005 Sep 14; 25(9):1897-902. PubMed ID: 15994444
    [Abstract] [Full Text] [Related]

  • 5. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B, Fonseca V.
    Vascul Pharmacol; 2006 Jul 14; 45(1):29-35. PubMed ID: 16777491
    [Abstract] [Full Text] [Related]

  • 6. [Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy].
    Bełtowski J, Wójcicka G, Jamroz A.
    Postepy Hig Med Dosw; 2003 Jul 14; 57(2):199-217. PubMed ID: 12866356
    [Abstract] [Full Text] [Related]

  • 7. Modulation of peroxisome proliferator-activated receptors (PPARs) by PPAR(alpha)- and PPAR(gamma)-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes.
    Ibabe A, Herrero A, Cajaraville MP.
    Toxicol In Vitro; 2005 Sep 14; 19(6):725-35. PubMed ID: 15964169
    [Abstract] [Full Text] [Related]

  • 8. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
    Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ.
    Am J Ther; 2007 Sep 14; 14(1):49-62. PubMed ID: 17303976
    [Abstract] [Full Text] [Related]

  • 9. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P, Rose M, Singh M.
    Pharmacology; 2007 Sep 14; 80(1):1-10. PubMed ID: 17496434
    [Abstract] [Full Text] [Related]

  • 10. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W.
    Pharmacol Rev; 2006 Dec 14; 58(4):726-41. PubMed ID: 17132851
    [Abstract] [Full Text] [Related]

  • 11. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P, Plutzky J.
    Am J Cardiol; 2007 Feb 19; 99(4A):27B-40B. PubMed ID: 17307056
    [Abstract] [Full Text] [Related]

  • 12. Peroxisome proliferator-activated receptors and acute lung injury.
    Cuzzocrea S.
    Curr Opin Pharmacol; 2006 Jun 19; 6(3):263-70. PubMed ID: 16580256
    [Abstract] [Full Text] [Related]

  • 13. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
    Chetty VT, Sharma AM.
    Vascul Pharmacol; 2006 Jul 19; 45(1):46-53. PubMed ID: 16713364
    [Abstract] [Full Text] [Related]

  • 14. Peroxisome proliferator-activated receptor alpha and gamma ligands differentially affect smooth muscle cell proliferation and migration.
    Zahradka P, Wright B, Fuerst M, Yurkova N, Molnar K, Taylor CG.
    J Pharmacol Exp Ther; 2006 May 19; 317(2):651-9. PubMed ID: 16407462
    [Abstract] [Full Text] [Related]

  • 15. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?
    Becker J, Delayre-Orthez C, Frossard N, Pons F.
    Fundam Clin Pharmacol; 2006 Oct 19; 20(5):429-47. PubMed ID: 16968414
    [Abstract] [Full Text] [Related]

  • 16. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB.
    Curr Opin Nephrol Hypertens; 2008 May 19; 17(3):282-5. PubMed ID: 18408479
    [Abstract] [Full Text] [Related]

  • 17. Vascular effects of PPARgamma activators - from bench to bedside.
    Marx N, Walcher D.
    Prog Lipid Res; 2007 Nov 19; 46(6):283-96. PubMed ID: 17637478
    [Abstract] [Full Text] [Related]

  • 18. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A.
    Acta Med Indones; 2006 Nov 19; 38(3):160-6. PubMed ID: 17119268
    [Abstract] [Full Text] [Related]

  • 19. [PPARs: physiological functions and pharmacological roles of agonists in human diseases. Note II].
    Filip-Ciubotaru F, Manciuc C, Grigore C, Foia L.
    Rev Med Chir Soc Med Nat Iasi; 2012 Nov 19; 116(1):240-7. PubMed ID: 23077903
    [Abstract] [Full Text] [Related]

  • 20. [Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control].
    Bocher V, Chinetti G, Fruchart JC, Staels B.
    J Soc Biol; 2002 Nov 19; 196(1):47-52. PubMed ID: 12134632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 81.